Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.55 |
| ▸ | NOS1 | P29475 | 11/20 | 0.55 |
| ▸ | NOS3 | P29474 | 8/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.41 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.39 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.39 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.39 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.39 |
| ▸ | ATP4A | P20648 | 1/20 | 0.39 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.39 |
| ▸ | ATP4B | P51164 | 1/20 | 0.39 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.39 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864599 | 0.92 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9PDE3B | |
| SCHEMBL4867989 | 0.91 | NOS2 (0.56) | NOS2NOS1NOS3CYP2C9PDE3B | |
| SCHEMBL4863062 | 0.89 | NOS2 (0.57) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4871273 | 0.87 | NOS2 (0.53) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4867916 | 0.86 | NOS2 (0.46) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL4866627 | 0.85 | NOS2 (0.46) | NOS2NOS1NOS3CYP2C9 | |
| SCHEMBL5033970 | 0.84 | NOS2 (0.67) | NOS2NOS1NOS3CYP2C9HTR1A | |
| SCHEMBL4866623 | 0.84 | NOS2 (0.45) | NOS2NOS1NOS3CYP2C9PDE3B | |
| SCHEMBL4861099 | 0.82 | NOS2 (0.45) | NOS2NOS1NOS3CYP2C9PDE10A | |
| SCHEMBL4866639 | 0.81 | NOS2 (0.55) | NOS2NOS1NOS3CYP2C9PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | claimed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | claimed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | claimed |
| EP-1599473-A1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2004076451-A1 | IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-09-10 | — | — | WO | claimed |
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1599473-A1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076451-A1 | IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | NOS2, NOS1, NOS3 | NOS2 1/4885NOS1 2/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.